Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy: a Single-arm, Multicenter Pilot Study

NCT05001971 is registered in ClinicalTrials.gov with Hunan Cancer Hospital as lead sponsor.

NCT NCT05001971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy: a Single-arm, Multicenter Pilot Study
Lead sponsor
Hunan Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2021
Completion date
April 15, 2025
Enrollment
65 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer